A survey of 150 US and European scientists finds most view electronic lab notebooks as inefficient, with 65% reporting experiment duplication due to inaccessible data and only 7% able to adapt ELNs to new workflows independently.
The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
Teams complete whole human genome sequencing and analysis in under four hours, demonstrating potential for same-day NICU workflows.
The CLIA-certified facility is now authorized to operate in all 50 states, expanding biomarker testing capabilities nationwide.
The pathologist served as joint plaintiff in successful lawsuit challenging FDA regulation of LDTs as medical devices.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The laboratory services company updates full-year guidance following continued momentum in diagnostics and central laboratory businesses.
Analysis of international surveillance data shows rising resistance to last-line antibiotics, with significant regional variations in treatment outcomes.